Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 210 participants.
Also called NCT06820567
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 210 participants
- Sponsor
- Registry
-
NCT06820567
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06820567. Randomized; quadruple masking; primary purpose treatment. Start 2025-03-01 (anticipated); primary completion 2026-03-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD
- Condition
- Chronic Kidney Diseases
- Condition
- Diabetes Type 2
- Intervention (Drug)
- Dapagliflozin (DAPA)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Assiut University
Record details
- Record id
cardio:ct-nct06820567- Content hash
455bfee524015d0b00dbeb32285823dc926836a61189b3dae506312c81f5fda3